Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Moderna, Inc. MRNA

Healthcare  —  Biotechnology
198.88 4.06 2.08% as of 25 Sep
Market cap
$78.8B
P/E
0.0×
S&P 500 Member
Indexes indicate stock being part of an index
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Moderna, Inc. (MRNA) Business Profile

Updated before January 2025

Company Overview

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company that specializes in the development and commercialization of messenger RNA (mRNA) technology-based therapeutics and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna was established by a group of scientists and entrepreneurs, including Derrick Rossi, Noubar Afeyan, Kenneth Chien, and Robert Langer. The company’s mission is to harness the power of mRNA to create transformative medicines for patients across the globe.

Moderna gained global recognition during the COVID-19 pandemic for its rapid development of the mRNA-based COVID-19 vaccine, branded as Spikevax. The company is led by Stéphane Bancel, who has served as Chief Executive Officer since 2011. Other key members of the leadership team include Juan Andres (Chief Technical Operations and Quality Officer), Stephen Hoge (President), and David Meline (Chief Financial Officer). Moderna’s innovative approach to biotechnology has positioned it as a leader in the field of mRNA technology.

Core Business Segments

Moderna operates primarily in the biotechnology and pharmaceutical sectors, focusing on the development of mRNA-based therapeutics and vaccines. Its core business segments include:

1. Vaccines

Moderna’s vaccine portfolio is its most prominent business segment. The company develops vaccines for infectious diseases using its proprietary mRNA platform. Key products include:

  • Spikevax (COVID-19 Vaccine): Moderna’s flagship product, which played a critical role in combating the COVID-19 pandemic. Spikevax has been authorized for emergency use and full approval in multiple countries.
  • Seasonal Influenza Vaccine: Moderna is developing an mRNA-based flu vaccine to provide broader protection against seasonal influenza strains.
  • RSV Vaccine: The company is working on a vaccine for respiratory syncytial virus (RSV), targeting vulnerable populations such as older adults.
  • Cytomegalovirus (CMV) Vaccine: Moderna is advancing a vaccine candidate for CMV, a leading cause of birth defects.

2. Therapeutics

Moderna is also exploring the application of mRNA technology in therapeutics. Key areas of focus include:

  • Oncology: Developing personalized cancer vaccines and immunotherapies to target specific tumor types.
  • Rare Diseases: Addressing genetic disorders by delivering mRNA-based treatments to correct or replace defective genes.
  • Cardiovascular Diseases: Investigating mRNA therapies for heart failure and other cardiovascular conditions.

3. Platform Technologies

Moderna’s proprietary mRNA platform is the foundation of its business. The company continues to invest in platform innovation to expand its capabilities in drug discovery, delivery, and manufacturing.

Business Model

Moderna’s business model is centered around leveraging its mRNA platform to develop and commercialize innovative medicines. The company generates revenue primarily through:

  • Product Sales: Revenue from the sale of its COVID-19 vaccine, Spikevax, constitutes a significant portion of its income.
  • Collaborations and Partnerships: Moderna collaborates with governments, non-profits, and pharmaceutical companies to co-develop and distribute its products. These partnerships often include upfront payments, milestone payments, and royalties.
  • Research Grants: The company receives funding from organizations such as the U.S. government and the Coalition for Epidemic Preparedness Innovations (CEPI) to support its research and development efforts.

Moderna’s vertically integrated approach allows it to control the entire value chain, from research and development to manufacturing and distribution. This integration ensures efficiency and scalability in bringing its products to market.

Strategic Direction

Moderna’s strategic priorities include:

  • Pipeline Expansion: The company is focused on broadening its pipeline of mRNA-based vaccines and therapeutics. This includes advancing candidates for infectious diseases, oncology, and rare genetic disorders.
  • Global Accessibility: Moderna aims to make its products accessible to underserved populations by establishing manufacturing facilities and partnerships in regions such as Africa and Asia.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable manufacturing practices and minimizing waste.
  • New Product Categories: Moderna is exploring the potential of mRNA technology in areas such as regenerative medicine and autoimmune diseases.

Competitive Landscape

Moderna operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • Pfizer/BioNTech: A major competitor in the mRNA vaccine space, particularly for COVID-19 vaccines.
  • CureVac: Another mRNA-focused biotech company developing vaccines and therapeutics.
  • Novavax: Competes in the vaccine market with its protein-based COVID-19 vaccine.
  • Gilead Sciences and Amgen: Compete in the broader biotechnology sector, particularly in oncology and rare diseases.

Moderna differentiates itself through its proprietary mRNA platform, robust pipeline, and rapid response capabilities.

Risk Factors

Moderna faces several risks that could impact its business:

  • Market Dependence: A significant portion of Moderna’s revenue comes from its COVID-19 vaccine. A decline in demand or competition from other vaccines could affect its financial performance.
  • Regulatory Challenges: The company’s products must meet stringent regulatory requirements, which can delay approvals and increase costs.
  • Supply Chain Disruptions: Dependence on raw materials and manufacturing partners exposes Moderna to supply chain risks.
  • Intellectual Property: The company faces potential legal challenges related to patent disputes and intellectual property rights.
  • Economic and Geopolitical Factors: Global economic conditions and geopolitical tensions can impact Moderna’s operations and market access.

Recent Developments

  • Updated COVID-19 Vaccine: Moderna has developed updated versions of its COVID-19 vaccine to address emerging variants, such as Omicron.
  • New Manufacturing Facilities: The company announced plans to build mRNA manufacturing facilities in Africa and Canada to enhance global vaccine production.
  • Collaborations: Moderna has entered into partnerships with pharmaceutical companies and research institutions to advance its pipeline.
  • AI Integration: The company is leveraging artificial intelligence to accelerate drug discovery and optimize manufacturing processes.

Investment Considerations

Strengths:

  • Innovative Technology: Moderna’s mRNA platform is a game-changer in biotechnology.
  • Strong Pipeline: A diverse pipeline of vaccines and therapeutics provides growth opportunities.
  • Global Recognition: The success of Spikevax has enhanced Moderna’s brand and credibility.

Risks:

  • Revenue Concentration: Heavy reliance on COVID-19 vaccine sales.
  • Regulatory and Legal Risks: Potential delays and challenges in product approvals.
  • Market Competition: Intense competition from established pharmaceutical companies.

Conclusion

Moderna, Inc. is a pioneering biotechnology company that has revolutionized the field of mRNA-based medicines. With a robust pipeline, innovative technology, and a commitment to global health, Moderna is well-positioned for future growth. However, investors should consider the risks associated with market dependence and regulatory challenges. As the company expands its portfolio and global footprint, it remains a key player in the biotechnology industry.